<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&lt;strong&gt;UPDATED INFORMATION&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Time&lt;/strong&gt;&lt;/p&gt;&lt;div&gt;The open session for the December 18, 2014 joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will be begin at &lt;u&gt;8 a.m. to 9:15 a.m.&lt;/u&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;The closed session will begin following the adjournment of the open session and end at 5 p.m.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;On December 18, 2014, from 8 a.m. to 9:15 a.m., the meeting will be open to allow oral presentations from the public. Following the adjournment of the open session until 5 p.m., the meeting will be closed to permit discussion of whether FDA should permit further clinical development of an existing investigational drug product, which will include the review of trade secret and/or confidential information&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;The time for oral presentations from the public has changed to start at approximately &lt;u&gt;8:15 a.m.&lt;/u&gt; on December 18, 2014. The meeting will be open to the public from approximately 8:00 a.m. until the conclusion of the Open Public Hearing.&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;ORIGINAL INFORMATION&lt;/strong&gt;&lt;/p&gt;&lt;div class="table-responsive"&gt;&lt;table class="table" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" sizcache="12" sizset="0" style="width: 643px"&gt;&lt;tbody sizcache="11" sizset="0"&gt;&lt;tr id="rrtr0"&gt;&lt;th id="a1" bgcolor="#cccccc" valign="top" align="left" style="width: 71px"&gt;Center&lt;/th&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" align="left" style="width: 158px"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" align="left" style="width: 172px"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" align="left" style="width: 238px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr id="rrtr1"&gt;&lt;td id="rrtd0" height="61" valign="top" headers="a1" style="width: 71px"&gt;CDER&lt;/td&gt;&lt;td id="rrtd1" valign="top" headers="a2" style="width: 158px"&gt;December 18, 2014&lt;/td&gt;&lt;td id="rrtd2" valign="top" headers="a3" style="width: 172px"&gt;&lt;p&gt;8:00 a.m. to 9:15 a.m.&lt;/p&gt;&lt;p&gt;(Open Session)&lt;/p&gt;&lt;p&gt;9:15 a.m. to 5:00 p.m.&lt;/p&gt;&lt;p&gt;(Closed Session)&lt;/p&gt;&lt;p&gt;&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;td id="rrtd3" valign="top" headers="a4" style="width: 238px"&gt;FDA White Oak Campus&lt;br /&gt;Building 31&lt;br /&gt;The Great Room (Rm. 1503)&lt;br /&gt;White Oak Conference Center&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;Silver Spring, Maryland&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;h3&gt;Agenda&lt;/h3&gt;&lt;p&gt;The meeting will be closed to permit discussion of whether FDA should permit further clinical development of an existing investigational drug product, which will include the review of trade secret and/or confidential information.&lt;/p&gt;&lt;h3&gt;Meeting Materials&lt;/h3&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;h3&gt;Background Material&lt;/h3&gt;&lt;ul sizcache="1" sizset="43"&gt;&lt;li sizcache="1" sizset="43"&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM380883')--]"&gt;&lt;u&gt;&lt;font color="#0066cc"&gt;2014 Meeting Materials, Drug Safety and Risk Management Advisory Committee&lt;/font&gt;&lt;/u&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h3&gt;Public Participation Information&lt;/h3&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before December 4, 2014.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:45 a.m. on December 18, 2014. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 24, 2014.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 25, 2014.&lt;/p&gt;&lt;h3&gt;Webcast Information&lt;/h3&gt;&lt;p sizcache="1" sizset="44"&gt;CDER will not be providing a webcast of the December 18, 2014, joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.&lt;/p&gt;&lt;h3&gt;Contact Information&lt;/h3&gt;&lt;ul sizcache="1" sizset="45"&gt;&lt;li sizcache="1" sizset="45"&gt;Kalyani Bhatt&lt;br /&gt;Center for Drug Evaluation and Research&lt;br /&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;WO31-2417&lt;br /&gt;Silver Spring, MD 20993-0002&lt;br /&gt;Phone: 301-796-9001&lt;br /&gt;Fax: 301-847-8533&lt;br /&gt;E-mail: &lt;a href="mailto:BRUDAC@fda.hhs.gov"&gt;BRUDAC@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul sizcache="5" sizset="30"&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)- follow the prompts to the desired center or product area&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Kalyani Bhatt at (301) 796-9001 at least 7 days in advance of the meeting.&lt;/p&gt;&lt;p&gt;Information regarding ground transportation, airport information, lodging, driving directions and visitor parking, and security can be accessed at: &lt;a target="" href="[!--$wcmUrl('link','UCM241740')--]"&gt;Public Meetings at the FDA White Oak Campus&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at &lt;a target="" href="/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1">&lt;p&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/p&gt;</wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
